Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings is well positioned by a combination of near-term execution strength and a credible multi-year growth runway, with 1Q26 revenue of $377.3 million beating consensus on outperformance across all segments and adjusted EPS of $1.46 ahead of expectations, while gross margin expanded to 67.0% and adjusted operating margin reached 34.2% on leverage from the SPECT divestiture and mix benefits. Its outlook is also supported by a de-risked 2026 setup and multiple catalysts, including FDA approval for PYLARIFY TruVu, tentative approval for PNT2003, and the August 13 PDUFA for MK6240, alongside management’s reiterated FY26 revenue guidance of $1.40 billion-$1.45 billion and adjusted EPS guidance of $5.00-$5.25. Longer term, the company’s leadership in radiopharmaceutical oncology and precision diagnostics, plus an underappreciated Alzheimer’s imaging opportunity that management sizes at roughly a $1.5 billion market by 2030 across about 430,000 annual scans, gives it multiple avenues for re-acceleration, margin expansion, and earnings upside beyond 2026.

Lantheus Holdings is facing a more fragile fundamental setup after the FDA issued a CRL for LNTH-2501 due to unresolved third-party manufacturing conditions, which delays a pipeline catalyst and introduces execution risk even though the agency did not flag data, safety, or efficacy concerns. At the same time, the company’s core Pylarify franchise is only stabilizing after a period of tension, with revenue of $241 million versus $228 million, just 9% revenue and 18% EPS beats in 1Q, and management still having to navigate two more quarters of TPT disadvantage before a potential 4Q26+ acceleration. While gross profit held at 67.0% and Neuraceq grew 14% sequentially to $35.4 million, the mix still reflects pressure from lower Pylarify net price and near-term margin dilution from Neuraceq and Evergreen manufacturing, leaving the business dependent on future catalysts rather than a clean current fundamental inflection.